1
|
Radtke T, Smith S, Nevitt SJ, Hebestreit H, Kriemler S. Physical activity and exercise training in cystic fibrosis. Cochrane Database Syst Rev 2022; 8:CD002768. [PMID: 35943025 PMCID: PMC9361297 DOI: 10.1002/14651858.cd002768.pub5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Physical activity (including exercise) may form an important part of regular care for people with cystic fibrosis (CF). This is an update of a previously published review. OBJECTIVES To assess the effects of physical activity interventions on exercise capacity by peak oxygen uptake, lung function by forced expiratory volume in one second (FEV1), health-related quality of life (HRQoL) and further important patient-relevant outcomes in people with cystic fibrosis (CF). SEARCH METHODS We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. The most recent search was on 3 March 2022. We also searched two ongoing trials registers: clinicaltrials.gov, most recently on 4 March 2022; and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), most recently on 16 March 2022. SELECTION CRITERIA: We included all randomised controlled trials (RCTs) and quasi-RCTs comparing physical activity interventions of any type and a minimum intervention duration of two weeks with conventional care (no physical activity intervention) in people with CF. DATA COLLECTION AND ANALYSIS Two review authors independently selected RCTs for inclusion, assessed methodological quality and extracted data. We assessed the certainty of the evidence using GRADE. MAIN RESULTS: We included 24 parallel RCTs (875 participants). The number of participants in the studies ranged from nine to 117, with a wide range of disease severity. The studies' age demographics varied: in two studies, all participants were adults; in 13 studies, participants were 18 years and younger; in one study, participants were 15 years and older; in one study, participants were 12 years and older; and seven studies included all age ranges. The active training programme lasted up to and including six months in 14 studies, and longer than six months in the remaining 10 studies. Of the 24 included studies, seven implemented a follow-up period (when supervision was withdrawn, but participants were still allowed to exercise) ranging from one to 12 months. Studies employed differing levels of supervision: in 12 studies, training was supervised; in 11 studies, it was partially supervised; and in one study, training was unsupervised. The quality of the included studies varied widely. This Cochrane Review shows that, in studies with an active training programme lasting over six months in people with CF, physical activity probably has a positive effect on exercise capacity when compared to no physical activity (usual care) (mean difference (MD) 1.60, 95% confidence interval (CI) 0.16 to 3.05; 6 RCTs, 348 participants; moderate-certainty evidence). The magnitude of improvement in exercise capacity is interpreted as small, although study results were heterogeneous. Physical activity interventions may have no effect on lung function (forced expiratory volume in one second (FEV1) % predicted) (MD 2.41, 95% CI ‒0.49 to 5.31; 6 RCTs, 367 participants), HRQoL physical functioning (MD 2.19, 95% CI ‒3.42 to 7.80; 4 RCTs, 247 participants) and HRQoL respiratory domain (MD ‒0.05, 95% CI ‒3.61 to 3.51; 4 RCTs, 251 participants) at six months and longer (low-certainty evidence). One study (117 participants) reported no differences between the physical activity and control groups in the number of participants experiencing a pulmonary exacerbation by six months (incidence rate ratio 1.28, 95% CI 0.85 to 1.94) or in the time to first exacerbation over 12 months (hazard ratio 1.34, 95% CI 0.65 to 2.80) (both high-certainty evidence); and no effects of physical activity on diabetic control (after 1 hour: MD ‒0.04 mmol/L, 95% CI ‒1.11 to 1.03; 67 participants; after 2 hours: MD ‒0.44 mmol/L, 95% CI ‒1.43 to 0.55; 81 participants; moderate-certainty evidence). We found no difference between groups in the number of adverse events over six months (odds ratio 6.22, 95% CI 0.72 to 53.40; 2 RCTs, 156 participants; low-certainty evidence). For other time points (up to and including six months and during a follow-up period with no active intervention), the effects of physical activity versus control were similar to those reported for the outcomes above. However, only three out of seven studies adding a follow-up period with no active intervention (ranging between one and 12 months) reported on the primary outcomes of changes in exercise capacity and lung function, and one on HRQoL. These data must be interpreted with caution. Altogether, given the heterogeneity of effects across studies, the wide variation in study quality and lack of information on clinically meaningful changes for several outcome measures, we consider the overall certainty of evidence on the effects of physical activity interventions on exercise capacity, lung function and HRQoL to be low to moderate. AUTHORS' CONCLUSIONS Physical activity interventions for six months and longer likely improve exercise capacity when compared to no training (moderate-certainty evidence). Current evidence shows little or no effect on lung function and HRQoL (low-certainty evidence). Over recent decades, physical activity has gained increasing interest and is already part of multidisciplinary care offered to most people with CF. Adverse effects of physical activity appear rare and there is no reason to actively discourage regular physical activity and exercise. The benefits of including physical activity in an individual's regular care may be influenced by the type and duration of the activity programme as well as individual preferences for and barriers to physical activity. Further high-quality and sufficiently-sized studies are needed to comprehensively assess the benefits of physical activity and exercise in people with CF, particularly in the new era of CF medicine.
Collapse
Affiliation(s)
- Thomas Radtke
- Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
| | - Sherie Smith
- Division of Child Health, Obstetrics & Gynaecology (COG), School of Medicine, University of Nottingham, Nottingham, UK
| | - Sarah J Nevitt
- Department of Health Data Science, University of Liverpool, Liverpool, UK
| | - Helge Hebestreit
- Paediatric Department, Julius-Maximilians University, Würzburg, Germany
| | - Susi Kriemler
- Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
| |
Collapse
|
2
|
Williams CA, Barker AR, Denford S, van Beurden SB, Bianchim MS, Caterini JE, Cox NS, Mackintosh KA, McNarry MA, Rand S, Schneiderman JE, Wells GD, Anderson P, Beever D, Beverley Z, Buckley R, Button B, Causer AJ, Curran M, Dwyer TJ, Gordon W, Gruet M, Harris RA, Hatziagorou E, Erik Hulzebos HJ, Kampouras A, Morrison L, Cámara MN, Reilly CM, Sawyer A, Saynor ZL, Shelley J, Spencer G, Stanford GE, Urquhart DS, Young R, Tomlinson OW. The Exeter Activity Unlimited statement on physical activity and exercise for cystic fibrosis: methodology and results of an international, multidisciplinary, evidence-driven expert consensus. Chron Respir Dis 2022; 19:14799731221121670. [PMID: 36068015 PMCID: PMC9459449 DOI: 10.1177/14799731221121670] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND The roles of physical activity (PA) and exercise within the management of cystic fibrosis (CF) are recognised by their inclusion in numerous standards of care and treatment guidelines. However, information is brief, and both PA and exercise as multi-faceted behaviours require extensive stakeholder input when developing and promoting such guidelines. METHOD On 30th June and 1st July 2021, 39 stakeholders from 11 countries, including researchers, healthcare professionals and patients participated in a virtual conference to agree an evidence-based and informed expert consensus about PA and exercise for people with CF. This consensus presents the agreement across six themes: (i) patient and system centred outcomes, (ii) health benefits, iii) measurement, (iv) prescription, (v) clinical considerations, and (vi) future directions. The consensus was achieved by a stepwise process, involving: (i) written evidence-based synopses; (ii) peer critique of synopses; (iii) oral presentation to consensus group and peer challenge of revised synopses; and (iv) anonymous voting on final proposed synopses for adoption to the consensus statement. RESULTS The final consensus document includes 24 statements which surpassed the consensus threshold (>80% agreement) out of 30 proposed statements. CONCLUSION This consensus can be used to support health promotion by relevant stakeholders for people with CF.
Collapse
Affiliation(s)
- Craig A Williams
- Children's Health and Exercise Research Centre, Sport and Health Science, 3286University of Exeter, Exeter, UK
- Royal Devon and Exeter NHS Foundation Trust Hospital, Exeter, UK
| | - Alan R Barker
- Children's Health and Exercise Research Centre, Sport and Health Science, 3286University of Exeter, Exeter, UK
| | - Sarah Denford
- 1980Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol, Bristol, UK
- Population Health Sciences, Bristol Medical School, 1980University of Bristol, Bristol, UK
- School of Psychological Science, 1980University of Bristol, Bristol, UK
| | | | - Mayara S Bianchim
- 7622University of Stirling, NMAHP Research Unit, University of Stirling, Stirling, UK
| | - Jessica E Caterini
- Translational Medicine, The Hospital for Sick Children, Toronto, Canada
- School of Medicine, Queen's University, Kingston, Canada
| | - Narelle S Cox
- Respiratory Research @ Alfred, Department of Immunology and Pathology, 2541Monash University, Melbourne, Australia
- Institute for Breathing and Sleep, Melbourne, Australia
| | - Kelly A Mackintosh
- Applied Sports, Technology, Exercise and Medicine (A-STEM) Research Centre, Department of Sport and Exercise Sciences, 7759Swansea University, Swansea, UK
| | - Melitta A McNarry
- Applied Sports, Technology, Exercise and Medicine (A-STEM) Research Centre, Department of Sport and Exercise Sciences, 7759Swansea University, Swansea, UK
| | - Sarah Rand
- Physiotherapy, UCL Great Ormond Street Institute of Child Health, London, UK
| | - Jane E Schneiderman
- Division of Respiratory Medicine, Hospital for Sick Children, Toronto, Canada
- Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Canada
| | - Greg D Wells
- Translational Medicine, The Hospital for Sick Children, Toronto, Canada
| | | | - Daniel Beever
- School of Health and Related Research, University of Sheffield, Sheffield, UK
| | - Z Beverley
- Adult Cystic Fibrosis Unit, 4964Royal Brompton and Harefield Hospitals, Guy's and St Thomas's NHS Foundation Trust, London, UK
| | - Ronan Buckley
- National Referral Centre for Adult Cystic Fibrosis, St Vincent's University Hospital, Dublin, Republic Of Ireland
| | - Brenda Button
- Faculty of Medicine Nursing and Health Sciences, 2541Monash University, Melbourne, Australia
- Department of Respiratory Medicine, 5392Alfred Health, Melbourne, Australia
| | - Adam J Causer
- Department for Health, 1555University of Bath, Bath, UK
| | - Máire Curran
- School of Allied Health, 8808University of Limerick, Limerick, Republic Of Ireland
- University Hospital Limerick, Limerick, Republic Of Ireland
- Health Research Institute, 8808University of Limerick, Limerick, Republic Of Ireland
| | - Tiffany J Dwyer
- Discipline of Physiotherapy, Sydney School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
- Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, Australia
| | | | - Mathieu Gruet
- 27017University of Toulon, IAPS Laboratory, Toulon, France
| | - Ryan A Harris
- Georgia Prevention Institute, Department of Medicine, 1421Augusta University, Augusta GA, United States Of America
| | - Elpis Hatziagorou
- Paediatric Pulmonology and CF Unit, 3rd Paediatric Department, 37782Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - H J Erik Hulzebos
- Department of Pediatrics, Child Development and Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Asterios Kampouras
- Paediatric Pulmonology and CF Unit, 3rd Paediatric Department, 37782Aristotle University of Thessaloniki, Thessaloniki, Greece
- Paediatric Department, 424 General Military Hospital, Thessaloniki, Greece
| | - Lisa Morrison
- West of Scotland Adult Cystic Fibrosis Unit, Queen Elizabeth University Hospital, Glasgow, UK
| | - Marietta N Cámara
- Hospital Carlos Van Buren, Department of Pediatrics, Division of Pulmonary, Cystic Fibrosis & Home Mechanical Ventilation, Valparaíso, Chile
- School of Medicine & Postgraduate, Department of Pediatrics, 28068Universidad de Valparaíso, Viña del Mar, Chile
| | - Clare M Reilly
- National Referral Centre for Adult Cystic Fibrosis, St Vincent's University Hospital, Dublin, Republic Of Ireland
| | - Abbey Sawyer
- Department of Physiotherapy, University of Melbourne, Parkville, Australia
- Institute for Breathing and Sleep, Austin Hospital, Heidelberg, Australia
| | - Zoe L Saynor
- School of Sport, Health and Exercise Science, Faculty of Science and Health, 6697University of Portsmouth, Portsmouth, UK
| | - James Shelley
- Applied Sports, Technology, Exercise and Medicine (A-STEM) Research Centre, Department of Sport and Exercise Sciences, 7759Swansea University, Swansea, UK
| | - Grace Spencer
- 1555Department of Psychology University of Bath, Bath, UK
| | - Gemma E Stanford
- Adult Cystic Fibrosis Unit, 4964Royal Brompton and Harefield Hospitals, Guy's and St Thomas's NHS Foundation Trust, London, UK
- National Heart and Lung Institute, Imperial College, London, UK
| | - Don S Urquhart
- Department of Paediatric Respiratory and Sleep Medicine, 59842Royal Hospital for Children and Young People, Edinburgh, UK
- Department of Child Life and Health, University of Edinburgh, Edinburgh, UK
| | - Rachel Young
- All Wales Adult Cystic Fibrosis Centre, 97605University Hospital Llandough, Llandough, UK
| | - Owen W Tomlinson
- Children's Health and Exercise Research Centre, Sport and Health Science, 3286University of Exeter, Exeter, UK
- Royal Devon and Exeter NHS Foundation Trust Hospital, Exeter, UK
| |
Collapse
|